{"transactions":[{"id":712607,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:15:48.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":5889,"price":50.8442,"value":299421.4938,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":41884,"source":{"system":"sec-edgar","filing":"0001536368-26-000007","document":"form4-07082026_090742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636826000007/form4-07082026_090742.xml","form_type":"4"}},{"id":712606,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-08T21:15:48.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":4111,"price":49.9834,"value":205481.7574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":47773,"source":{"system":"sec-edgar","filing":"0001536368-26-000007","document":"form4-07082026_090742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636826000007/form4-07082026_090742.xml","form_type":"4"}},{"id":744656,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T20:49:16.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":354,"price":35.8187,"value":12679.8198,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":51884,"source":{"system":"sec-edgar","filing":"0001536368-26-000004","document":"form4-06092026_080612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636826000004/form4-06092026_080612.xml","form_type":"4"}},{"id":744655,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T20:49:16.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":1867,"price":35.3573,"value":66012.0791,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":52238,"source":{"system":"sec-edgar","filing":"0001536368-26-000004","document":"form4-06092026_080612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636826000004/form4-06092026_080612.xml","form_type":"4"}},{"id":744654,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T20:49:16.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":7779,"price":34.2794,"value":266659.4526,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person ."}],"balance_after":54105,"source":{"system":"sec-edgar","filing":"0001536368-26-000004","document":"form4-06092026_080612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636826000004/form4-06092026_080612.xml","form_type":"4"}},{"id":901021,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T01:01:09.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":17126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date."}],"balance_after":17126,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":17126},"source":{"system":"sec-edgar","filing":"0001536368-26-000003","document":"form4-02182026_010205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636826000003/form4-02182026_010205.xml","form_type":"4"}},{"id":945782,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:48:01.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026."}],"balance_after":40000,"derivative":{"exercise_price":8.17,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001536368-26-000002","document":"form4-01062026_090157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000153636826000002/form4-01062026_090157.xml","form_type":"4"}},{"id":962014,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T22:58:14.000Z","date":"2025-12-17","kind":"exercise","planned":false,"acquired":false,"shares":15958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":3741,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":15958},"source":{"system":"sec-edgar","filing":"0001536368-25-000007","document":"form4-12192025_101209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636825000007/form4-12192025_101209.xml","form_type":"4"}},{"id":962013,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-19T22:58:14.000Z","date":"2025-12-17","kind":"exercise","planned":false,"acquired":true,"shares":15958,"price":1.12,"value":17872.96,"ownership":{"direct":true},"balance_after":30712,"source":{"system":"sec-edgar","filing":"0001536368-25-000007","document":"form4-12192025_101209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153636825000007/form4-12192025_101209.xml","form_type":"4"}},{"id":975672,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-09T22:35:02.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":15600,"derivative":{"exercise_price":7.9,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001536368-25-000006","document":"form4-12092025_101258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000153636825000006/form4-12092025_101258.xml","form_type":"4"}},{"id":975671,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T22:35:02.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":7.9,"value":79000.0,"ownership":{"direct":true},"balance_after":84200,"source":{"system":"sec-edgar","filing":"0001536368-25-000006","document":"form4-12092025_101258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000153636825000006/form4-12092025_101258.xml","form_type":"4"}},{"id":978776,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T22:47:34.000Z","date":"2025-12-04","kind":"exercise","planned":false,"acquired":false,"shares":5534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":0,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":5534},"source":{"system":"sec-edgar","filing":"0001536368-25-000004","document":"form4-12052025_101227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000153636825000004/form4-12052025_101227.xml","form_type":"4"}},{"id":978775,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-05T22:47:34.000Z","date":"2025-12-04","kind":"exercise","planned":false,"acquired":true,"shares":5534,"price":3.75,"value":20752.5,"ownership":{"direct":true},"balance_after":74200,"source":{"system":"sec-edgar","filing":"0001536368-25-000004","document":"form4-12052025_101227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000153636825000004/form4-12052025_101227.xml","form_type":"4"}},{"id":1142015,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-19T21:33:36.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":9.51,"expiration_date":"2035-05-18","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001549595-25-000082","document":"wk-form4_1747690408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000154959525000082/wk-form4_1747690408.xml","form_type":"4"}},{"id":1226757,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T22:27:04.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":6.33,"exercise_date":"2024-06-11","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-25-006616","document":"form4-03042025_100357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588925006616/form4-03042025_100357.xml","form_type":"4"}},{"id":1226756,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T22:27:04.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":false,"shares":27666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":5534,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":27666},"source":{"system":"sec-edgar","filing":"0001415889-25-006616","document":"form4-03042025_100357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588925006616/form4-03042025_100357.xml","form_type":"4"}},{"id":1226755,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-04T22:27:04.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":20500,"price":6.33,"value":129765.0,"ownership":{"direct":true},"balance_after":68666,"source":{"system":"sec-edgar","filing":"0001415889-25-006616","document":"form4-03042025_100357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588925006616/form4-03042025_100357.xml","form_type":"4"}},{"id":1226754,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-04T22:27:04.000Z","date":"2025-03-03","kind":"exercise","planned":false,"acquired":true,"shares":27666,"price":3.75,"value":103747.5,"ownership":{"direct":true},"balance_after":48166,"source":{"system":"sec-edgar","filing":"0001415889-25-006616","document":"form4-03042025_100357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588925006616/form4-03042025_100357.xml","form_type":"4"}},{"id":1276599,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:39:40.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":15368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":15368,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":15368},"source":{"system":"sec-edgar","filing":"0001415889-25-003523","document":"form4-02102025_100237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588925003523/form4-02102025_100237.xml","form_type":"4"}},{"id":1309793,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:46:39.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025."}],"balance_after":35000,"derivative":{"exercise_price":8.26,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-000792","document":"form4-01062025_090135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588925000792/form4-01062025_090135.xml","form_type":"4"}},{"id":1451683,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-18T20:06:00.000Z","date":"2024-07-17","kind":"gift","planned":false,"acquired":false,"shares":54027,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001549595-24-000100","document":"wk-form4_1721333153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000154959524000100/wk-form4_1721333153.xml","form_type":"4"}},{"id":1478577,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:25:48.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":25600,"derivative":{"exercise_price":7.9,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":25600},"source":{"system":"sec-edgar","filing":"0001415889-24-016913","document":"form4-06142024_080645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588924016913/form4-06142024_080645.xml","form_type":"4"}},{"id":1491503,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-04T22:48:45.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":false,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":33200,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-24-015475","document":"form4-06042024_100642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588924015475/form4-06042024_100642.xml","form_type":"4"}},{"id":1491502,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:48:45.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":20500,"price":3.75,"value":76875.0,"ownership":{"direct":true},"balance_after":20500,"source":{"system":"sec-edgar","filing":"0001415889-24-015475","document":"form4-06042024_100642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000141588924015475/form4-06042024_100642.xml","form_type":"4"}},{"id":1508606,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-20T23:26:08.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":16.19,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001549595-24-000068","document":"wk-form4_1716247551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000154959524000068/wk-form4_1716247551.xml","form_type":"4"}},{"id":1543800,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-11T00:39:19.000Z","date":"2024-04-08","kind":"grant","planned":false,"acquired":true,"shares":37882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date."}],"balance_after":37882,"derivative":{"exercise_price":18.3,"expiration_date":"2034-04-08","underlying":"Common Stock","underlying_shares":37882},"source":{"system":"sec-edgar","filing":"0001415889-24-010678","document":"form4-04112024_120413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010678/form4-04112024_120413.xml","form_type":"4"}},{"id":1853940,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T20:56:37.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":20500,"derivative":{"exercise_price":6.33,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919123037396/doc4.xml","form_type":"4"}},{"id":1904073,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2023-05-04T23:56:31.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":9.44,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-027507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919123027507/doc4.xml","form_type":"4"}},{"id":2226975,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-18T00:23:22.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":53700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B)  one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":53700,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":53700},"source":{"system":"sec-edgar","filing":"0001209191-22-038201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919122038201/doc4.xml","form_type":"4"}},{"id":2279027,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2022-05-06T21:23:28.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":10.39,"expiration_date":"2032-05-04","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-027662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919122027662/doc4.xml","form_type":"4"}},{"id":2421309,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option","published_at":"2022-01-31T22:33:15.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company."}],"balance_after":85000,"derivative":{"exercise_price":3.19,"expiration_date":"2032-01-30","underlying":"Common stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-22-005689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919122005689/doc4.xml","form_type":"4"}},{"id":2662979,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T23:48:29.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":16625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":16625,"derivative":{"exercise_price":19.03,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":16625},"source":{"system":"sec-edgar","filing":"0001209191-21-041745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919121041745/doc4.xml","form_type":"4"}},{"id":2698274,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2021-05-24T23:49:13.000Z","date":"2021-05-06","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":27.38,"expiration_date":"2031-05-05","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-035538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919121035538/doc4.xml","form_type":"4"}},{"id":2890647,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option","published_at":"2021-01-29T21:30:08.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 28, 2022), subject to the director's continued service with the Company."}],"balance_after":33000,"derivative":{"exercise_price":9.14,"expiration_date":"2031-01-27","underlying":"Common stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001209191-21-006097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919121006097/doc4.xml","form_type":"4"}},{"id":3114374,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-10T21:09:15.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":28515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36 of the shares subject to the option shall vest on each monthly anniversary of the date of grant."}],"balance_after":28515,"derivative":{"exercise_price":35.92,"expiration_date":"2030-06-08","underlying":"Common Stock","underlying_shares":28515},"source":{"system":"sec-edgar","filing":"0001209191-20-035596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000120919120035596/doc4.xml","form_type":"4"}},{"id":3228254,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option","published_at":"2020-03-04T22:10:44.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (March 2, 2021), subject to the director's continued service with the Company."}],"balance_after":180000,"derivative":{"exercise_price":1.26,"expiration_date":"2030-03-01","underlying":"Common stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001209191-20-016247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919120016247/doc4.xml","form_type":"4"}},{"id":3397262,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-05T00:31:31.000Z","date":"2019-10-04","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019."}],"balance_after":7500,"derivative":{"exercise_price":0.6391,"expiration_date":"2029-10-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-052619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119052619/doc4.xml","form_type":"4"}},{"id":3506201,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-05-31T20:24:57.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 monthly installments following the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":4.22,"expiration_date":"2029-05-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-033658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119033658/doc4.xml","form_type":"4"}},{"id":3631851,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting-Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-02-26T21:49:28.000Z","date":"2019-01-11","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on May 26, 2019."}],"balance_after":35000,"derivative":{"exercise_price":9.27,"expiration_date":"2029-01-10","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-013586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119013586/doc4.xml","form_type":"4"}},{"id":3653246,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:14:00.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":8750,"price":235,"value":2056250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":180.98,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001567619-19-004572","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761919004572/doc1.xml","form_type":"4"}},{"id":3653245,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:14:00.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":11000,"price":235,"value":2585000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":78.58,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001567619-19-004572","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761919004572/doc1.xml","form_type":"4"}},{"id":3653244,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:14:00.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":3095,"price":235,"value":727325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":24.18,"expiration_date":"2026-06-09","underlying":"Common Stock","underlying_shares":3095},"source":{"system":"sec-edgar","filing":"0001567619-19-004572","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761919004572/doc1.xml","form_type":"4"}},{"id":3653243,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:14:00.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":4716,"price":235,"value":1108260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":20.91,"expiration_date":"2025-07-27","underlying":"Common Stock","underlying_shares":4716},"source":{"system":"sec-edgar","filing":"0001567619-19-004572","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761919004572/doc1.xml","form_type":"4"}},{"id":3653242,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:14:00.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":49687,"price":235,"value":11676445.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":49687},"source":{"system":"sec-edgar","filing":"0001567619-19-004572","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761919004572/doc1.xml","form_type":"4"}},{"id":3653241,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T14:14:00.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":27344,"price":235,"value":6425840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":27344},"source":{"system":"sec-edgar","filing":"0001567619-19-004572","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761919004572/doc1.xml","form_type":"4"}},{"id":3686910,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-25T21:38:24.000Z","date":"2019-01-23","kind":"sale","acquired":false,"shares":14800,"price":1.0528,"value":15581.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.095, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":22200,"source":{"system":"sec-edgar","filing":"0001209191-19-005351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919119005351/doc4.xml","form_type":"4"}},{"id":3689641,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option","published_at":"2019-01-23T21:48:13.000Z","date":"2019-01-21","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company."}],"balance_after":180000,"derivative":{"exercise_price":1.16,"expiration_date":"2029-01-20","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001209191-19-004985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919119004985/doc4.xml","form_type":"4"}},{"id":3797945,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-10-03T21:05:02.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and is immediately exercisable."}],"balance_after":22344,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-18-003657","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761918003657/doc1.xml","form_type":"4"}},{"id":3797944,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:05:02.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":500,"price":171.896,"value":85948.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.38 to $172.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-18-003657","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761918003657/doc1.xml","form_type":"4"}},{"id":3797943,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:05:02.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":4500,"price":170.1958,"value":765881.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.00 to $170.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":500,"source":{"system":"sec-edgar","filing":"0001567619-18-003657","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761918003657/doc1.xml","form_type":"4"}},{"id":3797942,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:05:02.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":5000,"price":3.648,"value":18240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001567619-18-003657","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000156761918003657/doc1.xml","form_type":"4"}},{"id":3883998,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-06-25T20:48:53.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 monthly installments following the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":8.98,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-039411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919118039411/doc4.xml","form_type":"4"}},{"id":3890327,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"exercise","acquired":false,"shares":1953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":5859,"derivative":{"exercise_price":24.18,"expiration_date":"2026-06-09","underlying":"Common Stock","underlying_shares":1953},"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890326,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"exercise","acquired":false,"shares":3096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":4716,"derivative":{"exercise_price":20.91,"expiration_date":"2025-07-27","underlying":"Common Stock","underlying_shares":3096},"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890325,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"exercise","acquired":false,"shares":27343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option is fully vested and is immediately exercisable."}],"balance_after":27344,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":27343},"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890324,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-15","kind":"sale","acquired":false,"shares":4,"price":177.79,"value":711.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890323,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-15","kind":"sale","acquired":false,"shares":5601,"price":177.1217,"value":992058.6417,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate of sales effected on the same day at different prices"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $176.68 to $177.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":4,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890322,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-15","kind":"sale","acquired":false,"shares":1235,"price":175.6434,"value":216919.599,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate of sales effected on the same day at different prices"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $175.36 to $176.10 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":5605,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890321,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"sale","acquired":false,"shares":1541,"price":182.3467,"value":280996.2647,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate of sales effected on the same day at different prices"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $182.31 to $182.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6840,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890320,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"sale","acquired":false,"shares":2411,"price":181.4783,"value":437544.1813,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate of sales effected on the same day at different prices"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $181.01 to $181.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":8381,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890319,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"sale","acquired":false,"shares":28440,"price":180.2751,"value":5127023.844,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate of sales effected on the same day at different prices"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $180.00 to $180.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":10792,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890318,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"exercise","acquired":true,"shares":1953,"price":24.18,"value":47223.54,"ownership":{"direct":true},"balance_after":39232,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890317,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"exercise","acquired":true,"shares":3096,"price":20.91,"value":64737.36,"ownership":{"direct":true},"balance_after":37279,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3890316,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T21:00:48.000Z","date":"2018-06-14","kind":"exercise","acquired":true,"shares":27343,"price":3.648,"value":99747.264,"ownership":{"direct":true},"balance_after":34183,"source":{"system":"sec-edgar","filing":"0001140361-18-028996","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028996/doc1.xml","form_type":"4"}},{"id":3893456,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-14T21:05:58.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":8750,"derivative":{"exercise_price":180.98,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001140361-18-028643","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118028643/doc1.xml","form_type":"4"}},{"id":3957898,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-24T20:30:40.000Z","date":"2018-04-20","kind":"sale","acquired":false,"shares":100,"price":133.6,"value":13360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."}],"balance_after":6840,"source":{"system":"sec-edgar","filing":"0001140361-18-019388","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118019388/doc1.xml","form_type":"4"}},{"id":3957897,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-24T20:30:40.000Z","date":"2018-04-20","kind":"sale","acquired":false,"shares":4000,"price":132.8097,"value":531238.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $132.55 to $133.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":6940,"source":{"system":"sec-edgar","filing":"0001140361-18-019388","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118019388/doc1.xml","form_type":"4"}},{"id":3957896,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-24T20:30:40.000Z","date":"2018-04-20","kind":"sale","acquired":false,"shares":900,"price":131.9772,"value":118779.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $131.22 to $132.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":10940,"source":{"system":"sec-edgar","filing":"0001140361-18-019388","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036118019388/doc1.xml","form_type":"4"}},{"id":4091251,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2018-01-24T21:47:03.000Z","date":"2018-01-22","kind":"grant","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant."}],"balance_after":185000,"source":{"system":"sec-edgar","filing":"0001209191-18-005152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919118005152/doc4.xml","form_type":"4"}},{"id":4171100,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-06T22:03:09.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":400,"price":86.2775,"value":34511.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $85.88 to $86.58 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11840,"source":{"system":"sec-edgar","filing":"0001140361-17-041152","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036117041152/doc1.xml","form_type":"4"}},{"id":4171099,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-06T22:03:09.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":2800,"price":85.2109,"value":238590.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $84.76 to $85.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":12240,"source":{"system":"sec-edgar","filing":"0001140361-17-041152","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036117041152/doc1.xml","form_type":"4"}},{"id":4171098,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-06T22:03:09.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":1800,"price":84.1494,"value":151468.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $83.74 to $84.69 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":15040,"source":{"system":"sec-edgar","filing":"0001140361-17-041152","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036117041152/doc1.xml","form_type":"4"}},{"id":4226219,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-23T22:35:24.000Z","date":"2017-08-22","kind":"sale","acquired":false,"shares":10000,"price":75.1731,"value":751731.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $75.00 to $75.365 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":16840,"source":{"system":"sec-edgar","filing":"0001140361-17-033124","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036117033124/doc1.xml","form_type":"4"}},{"id":4273221,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-06-23T21:22:15.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":11000,"derivative":{"exercise_price":78.58,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001140361-17-026014","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1536368/000114036117026014/doc1.xml","form_type":"4"}},{"id":4353411,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-04-13T01:05:17.000Z","date":"2017-04-12","kind":"grant","acquired":true,"shares":4528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017."}],"balance_after":4528,"derivative":{"exercise_price":10,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":4528},"source":{"system":"sec-edgar","filing":"0001209191-17-026754","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919117026754/doc4.xml","form_type":"4"}},{"id":4410251,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option","published_at":"2017-03-02T21:53:11.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company."}],"balance_after":120000,"derivative":{"exercise_price":2.31,"expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-17-016727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919117016727/doc4.xml","form_type":"4"}},{"id":4558447,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31442,"kind":"person","name":"Kunkel Lori Anne","position":1,"cik":"0001536368","reported_name":"Kunkel Lori Anne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option","published_at":"2016-11-14T20:54:43.000Z","date":"2016-11-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the 2010 Stock Incentive Plan and will vest over a period of four years with 25% of the stock options vesting on November 11, 2017, and an additional 6.25% of the shares during each successive three-month period thereafter until the options are fully vested on November 11, 2020, subject to continued service on the Company's Board."}],"balance_after":25000,"derivative":{"exercise_price":3.36,"expiration_date":"2026-11-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-16-149709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919116149709/doc4.xml","form_type":"4"}}]}